Peptide pills for brain diseases? Reality and future perspectives

Therapeutic Delivery

Volumn 4, Issue 4, 2013, Pages 479-501

  Serrano Lopez, Dolores Remedios ^a   Lalatsa, Aikaterini ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; AXCESS; CALCITONIN; CYCLOSPORIN; CYCLOSPORIN A; DESMOPRESSIN; DESMOPRESSIN ACETATE; GLATIRAMER; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; INSULIN; KAPPA OPIATE RECEPTOR AGONIST; LEUCINE ENKEPHALIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LEUPRORELIN; LYPRESSIN; NANOPARTICLE; NEUROPEPTIDE; OCTREOTIDE; PARATHYROID HORMONE; PEPSIN A; PEPTIDE DERIVATIVE; PEPTIDE YY [3-36]; POLYMER; RAPIS MIST; RECOMBINANT HUMAN INSULIN; SALCATONIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

ANTINOCICEPTION; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN DISEASE; BRAIN INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICAL MODIFICATION; CONTROLLED RELEASE FORMULATION; DEGENERATIVE DISEASE; DEPRESSION; DIABETES INSIPIDUS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG PENETRATION; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; ECONOMIC ASPECT; ENCAPSULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME STABILITY; GASTROINTESTINAL TRACT; GENETIC ENGINEERING; HEALTH CARE NEED; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; NANOMEDICINE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROTEIN METABOLISM; RECOMBINANT DNA TECHNOLOGY; REVIEW; SINGLE DRUG DOSE;

EID: 84875957167     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.5     Document Type: Review

References (125)

1. Pichereau C, Allary C. Therapeutic peptides under the spotlight. In: European BioPharmaceutical Review. Winter issue. (2005
2. Lax R. The future of peptide development in the pharmaceutical industry. In: Pharmanufacturing: The International Peptide Review. World Business Journals, Pharmaceutical Division, London, UK (2010
3. Mi FL, Wu YY, Lin YH et al. Oral delivery of peptide drugs using nanoparticles self-assembled by poly(gamma-glutamic acid) and a chitosan derivative functionalized by trimethylation. Bioconjug. Chem. 19(6), 1248- 1255 (2008
4. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: Science and market. Drug Discov. Today 15(1-2), 40-56 (2010
5. McGonigle P. Peptide therapeutics for CNS indications. Biochem. Pharmacol. 83(5), 559-566 (2012
6. Reichert J. Development Trends for Peptide Therapeutics: A Comprehensive Quantitative Analysis of Peptide Therapeutics in Clinical Development. Peptide Therapeutic Foundation, CA, USA (2010
7. Decaffmeyer M, Thomas A, Brasseur, R. Les médicaments peptidiques: Mythe ou réalité ? Biotechnol. Agron. Soc. Environ. 12(1), 81-88 (2008
8. Ohlsen R. Drug Delivery Technology: Revolutionizing CNS Therapies. PharmaVision, Chistester, West Sussex, UK (2007
9. Brown LR. Commercial challenges of protein drug delivery. Expert Opin. Drug Deliv. 2(1), 29-42 (2005
10. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20(2-3), 153-214 (2003
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001
12. Ruggiero A, Villa CH, Bander E et al. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl Acad. Sci. USA 107(27), 12369-12374 (2010
13. Rekha MR, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes - future perspectives. Int. J. Pharm. 440(1), 48- 62 (2012
14. Sweeney P, Walker, JM. Peptide production. In: Enzymes of Molecular Biology. Burrell MM (Ed.). Human Press Inc, Totowa, NJ, USA, 290 (1993
15. Bernkop-Schnürch A. Oral Delivery of Macromolecular Drugs. Barriers, Strategies and Future trends. Springer Science and Business Media, LLC, NY, USA (2009
16. Langguth P, Bohner V, Heizmann J et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J. Control. Release 46, 39-57 (1997
17. Drasar BS, Hill MJ. Human Intestinal Flora. Academic Press, London, UK, 54-167 (1974
18. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557-570 (2012
19. Cone RA. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61(2), 75-85 (2009
20. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61(2), 158-171 (2009
21. Cereijido M, Ruiz O, Gonzalez-Mariscal L, Contreras RG, Balda MS, Garcia-Villegas MR. The paracellular pathway. In: Biological Barriers to Protein Delivery. Audus KL, Raub T (Eds). Plenum Press, NY, USA, 3-21 (1993
22. Rubas W, Cromwell ME, Shahrokh Z et al. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci 85(2), 165-169 (1996
23. Salamat-Miller N, Johnston TP. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294(1-2), 201-216 (2005
24. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46(1-3), 27-43 (2001
25. Overgaard CE, Sanzone KM, Spiczka KS, Sheff DR, Sandra A, Yeaman C. Deciliation is associated with dramatic remodeling of epithelial cell junctions and surface domains. Mol. Biol. Cell 20(1), 102-113 (2009
26. Lee GM, Diguiseppi J, Gawdi GM, Herman B. Chloral hydrate disrupts mitosis by increasing intracellular free calcium. J. Cell. Sci. 88(Pt 5), 603-612 (1987
27. Griffin BT, O'Driscoll CM. Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv. 2(12), 1633-1653 (2011
28. Shahbazi MA, Santos HA. Improving oral absorption via drug-loaded nanocarriers: Absorption mechanisms, intestinal models and rational fabrication. Curr. Drug Metab. 14(1), 28-56 (2012
29. Khafagy S, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv. Drug Deliv. Rev. 64(6), 531-539 (2012
30. Hu M, Li X. Barriers to oral bioavailability - An overview. In: Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications. Hu M, Li X (Eds). John Wiley & Sons, NJ, USA 568 (2011
31. Lee VHL, Dodda-Kashi S, Grass GM, Rubas W. Oral route of peptide and protein drug delivery. In: Peptide and Protein Drug Delivery. Lee VHL (Ed.). Marcel Dekker, Inc., NY, USA, 691-738 (1991
32. Des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release 116, 1-27 (2006
33. Li HF, Zou J, Bai RY, Xing YM, Nie JM, Diao Y. M cell in vitro model and its application in oral delivery of macromolecular drugs. Yao Xue Xue Bao, 46(12), 1429-1435 (2011
34. Shaji J, Patole V. Protein and peptide drug delivery: Oral approaches. Indian J. Pharm. Sci. 70(3), 269-277 (2008
35. Jha D, Mishra R, Gottschalk S et al. CyLoP-1: A novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes. Bioconjug. Chem. 22(3), 319-328 (2011
36. Berezowska I, Chung NN, Lemieux C, Wilkes BC, Schiller PW. Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[d-Cys-Gly-Phe-D(or l)-Cys]NH(2) retain high opioid activity. J. Med. Chem. 50(6), 1414-1417 (2007
37. Yan Z, Sun J, Chang Y et al. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: Synthesis, transepithelial transport, chemical stability and pharmacokinetics. Mol. Pharm. 8(2), 319-329 (2011
38. Hayouka Z, Levin A, Hurevich M et al. A comparative study of backbone versus side chain peptide cyclization: Application for HIV-1 integrase inhibitors. Bioorg. Med. Chem. 20(10), 3317-3322 (2012
39. Lalatsa A, Lee V, Malkinson JP, Zloh M, Schatzlein AG, Uchegbu IF. A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol. Pharm. 9(6), 1665-1680 (2012
40. Yamamoto A, Taniguchi T, Rikyuu K et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11, 1496-1500 (1994
41. Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52(1-2), 1-16 (1998
42. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Muranishi S. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: Implications in peptide delivery to the colon. J. Pharm. Pharmacol. 49(2), 164- 168 (1997
43. Kramer TH, Toth G, Haaseth RC et al. Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro. Life Sci. 48(9), 881- 886 (1991
44. Kanwar JR, Long BM, Kanwar RK. The use of cyclodextrins nanoparticles for oral delivery. Curr. Med. Chem. 18(14), 2079- 2085 (2011
45. Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schatzlein AG, Uchegbu IF. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol. Pharm. 9(6), 1764-1774 (2012
46. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromol. Biosci. 11(6), 748-764 (2011
47. Li P, Nielsen HM, Mullertz A. Oral delivery of peptides and proteins using lipid-based drug delivery systems. Expert Opin. Drug Deliv. (2012
48. Trapani A, Lopedota A, Franco M et al. A comparative study of chitosan and chitosan/ cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur. J. Pharm. Biopharm. 75(1), 26-32 (2010
49. Parquet N, Reigneau O, Humbert H et al. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 25(9), 965-968 (2000
50. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004
51. Kidron M, Dinh S, Menachem Y et al. A novel per-oral insulin formulation: Proof of concept study in non-diabetic subjects. Diabet. Med. 21(4), 354-357 (2004
52. Kapitza C, Arbit E, Abbas R et al. Oral insulproof of concept in Type 2 diabetes patients. Diabetes 52(Suppl. 1), A37 (2003
53. Werle M. Innovations in oral peptide delivery - focus on insulin. Drug Deliv. 28-29 (2007
54. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: Mechanistic studies. Curr. Drug Deliv. 2(2), 191-197 (2005
55. Qi R, Ping QN. Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J. Microencapsul. 21(1), 37-45 (2004
56. Park K, Kwon, IC, Park K. Oral protein delivery: Current status and future prospect. React. Funct. Polym. 71(280-287) (2011
57. Hoffman A, Qadri B. Eligen insulin - A system for the oral delivery of insulin for diabetes. IDrugs 11(6), 433-441 (2008
58. Arbit E, Kidron M. Oral insulin: The rationale for this approach and current developments. J. Diabetes Sci. Technol. 3(3), 562-567 (2009
59. Gordon Still J. Development of oral insulin: Progress and current status. Diabetes Metab. Res. Rev. 18(Suppl. 1), S29-37 (2002
60. Khedkar A, Iyer H, Anand A et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in Type 2 diabetes mellitus subjects. Diabetes Obes. Metab. 12(8), 659-664 (2010
61. Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al. A Phase III trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J. Bone Miner. Res. 27(8), 1821-1829 (2012
62. Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering effect of an oral insulin (Capsulin™) during an isoglycaemic clamp study in persons with Type 2 diabetes. Diabetes Obes. Metab. 12(1), 82-87 (2010
63. Walsh E, Fox JS, Leonard TW. Oral-absorption-enhancing drug-delivery technology. Pharm. Technol. 35, s12-14 (2011
64. Walsh EG, Adamczyk BE, Chalasani KB et al. Oral delivery of macromolecules: Rationale underpinning gastrointestinal permeation enhancement technology (GIPET). Ther. Deliv. 2(12), 1595-1610 (2011
65. Petrus AK, Fairchild TJ, Doyle RP. Traveling the vitamin B12 pathway: Oral delivery of protein and peptide drugs. Angew Chem. Int. Ed. Engl. 48(6), 1022-1028 (2009
66. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. Vitamin B12 as a carrier for the oral delivery of insulin. ChemMedChem 2(12), 1717-1721 (2007
67. Schwartz S, Geho B, Rosenberg L, Lau J. A 2-week randomized active comparator study of two HDV-insulin routes (SC and oral) and SC human insulin in patients with Type 1 diabetes. Diabetes 57(Suppl 1), A124 (2008
68. Gaillard PJ, Appeldoorn CC, Rip J et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J. Control. Release 164(3), 364-369 (2012
69. Gaillard S, Bartoli M, Castets F, Monneron A. Striatin, a calmodulin-dependent scaffolding protein, directly binds caveolin-1. FEBS Lett. 508(1), 49-52 (2001
70. Castets F, Rakitina T, Gaillard S, Moqrich A, Mattei MG, Monneron A. Zinedin. SG2NA, and striatin are calmodulin-binding, WD repeat proteins principally expressed in the brain. J. Bio. Chem. 275(26), 19970-19977 (2000
71. Halbsguth U, Rentsch KM, Eich-Hochli D, Diterich I, Fattinger K. Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: Bioavailability related to dosage and prior opioid exposure. Br. J. Clin. Pharmacol. 66(6), 781-791 (2008
72. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004
73. The Neurotechnology Industry 2008 Report. In: Pub ID: NEI1781046. NeuroInsights, L (2008
74. Ronaldson PT, Davis TP. Targeting blood-brain barrier changes during inflammatory pain: An opportunity for optimizing CNS drug delivery. Ther. Deliv. 2(8), 1015-1041 (2011
75. Hawkins RA, O'Kane RL, Simpson IA, Vina Jr. Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 136(1 Suppl.), 218S-226S (2006
76. Sorensen M, Steenberg B, Knipp GT et al. The effect of beta-turn structure on the permeation of peptides across monolayers of bovine brain microvessel endothelial cells. Pharm. Res. 14(10), 1341-1348 (1997
77. Fu XC, Wang GP, Liang WQ, Yu QS. Predicting blood-brain barrier penetration of drugs using an artificial neural network. Pharmazie 59(2), 126-130 (2004
78. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8(20), 927-933 (2003
79. Lalatsa A, Schätchlein AG, Uchegbu IF. Nanostructures overcoming the blood-brain barrier: Physiological considerations and mechanistic issues. In: Nanostructured Biomaterials for Overcoming Biological Barriers. Alonso M, Csaba N (Eds). Royal Society of Chemistry, London, UK, 329-363 (2012
80. Schirmacher A, Winters S, Fischer S et al. Electromagnetic fields (1.8 GHz) increase the permeability to sucrose of the blood-brain barrier in vitro. Bioelectromagnetics 21(5), 338- 345 (2000
81. Lalatsa A, Schätchlein AG, Uchegbu IF. Drug delivery across the blood-brain barrier. In: Comprehensive Biotechnology. Moo-Young, M, Butler M, Webb C, Moreira A, Grodzinski B, Cui Z (Eds). Elsevier, Amsterdam, The Netherlands, 657-668 (2011
82. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16(10), 1514-1519 (1999
83. Lennernas H, Lundgren E. Intestinal and blood-brain drug transport: Beyond involvement of a single transport function. Drug Discov. Today Technol. 1(4), 417-422 (2004
84. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51(4), 817-834 (2008
85. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37(1), 13-25 (2010
86. Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J. 10(3), 455-472 (2008
87. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137(1), 78-86 (2009
88. Witt KA, Davis TP. CNS drug delivery: Opioid peptides and the blood-brain barrier. AAPS J. 8(1), E76-E88 (2006
89. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42(5), 1083-1099; discussion 1099-1100 (1998
90. Rapoport SI. Osmotic opening of the blood- brain barrier: Principles, mechanism, and therapeutic applications. Cell. Mol. Neurobiol. 20(2), 217-230 (2000
91. Alexander B, Li X, Benjamin IS, Segal MB, Sherwood R, Preston JE. A quantitative evaluation of the permeability of the blood- brain barrier of portacaval shunted rats. Metab. Brain Dis. 15(2), 93-103 (2000
92. Emerich DF, Tracy MA, Ward KL et al. Biocompatibility of poly (dl-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant. 8(1), 47-58 (1999
93. Benoit JP, Faisant N, Venier-Julienne MC, Menei P. Development of microspheres for neurological disorders: From basics to clinical applications. J. Control. Release 65(1-2), 285-296 (2000
94. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37(1), 48-57 (2010
95. Neuwelt EA, Rapoport SI. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc. 43(2), 214-219 (1984
96. Salahuddin TS, Johansson BB, Kalimo H, Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta. Neuropathol. 77(1), 5-13 (1988
97. Rasheed A, Theja I, Silparani G, Lavanya Y, Kumar CKA. CNS targeted drug delivery: Current perspectives. JITPS 1(1), 9-18 (2010
98. Lindqvist A, Rip J, Gaillard PJ, Bjorkman S, Hammarlund-Udenaes M. Enhanced brain delivery of the opioid peptide DAMGO in glutathione PEGylated liposomes: A microdialysis study. Mol. Pharm. doi: 10.1021/ mp300272a (2012) (Epub ahead of print
99. Pardridge WM. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18(3), 157-167 (2010
100. Batrakova EV, Vinogradov SV, Robinson SM, Niehoff ML, Banks WA, Kabanov AV. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug. Chem. 16(4), 793-802 (2005
101. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2(1), 54-62 (2005
102. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2(1), 44-53 (2005
103. Deguchi Y, Naito Y, Ohtsuki S et al. Blood- brain barrier permeability of novel [d-arg2] dermorphin (1-4) analogs: Transport property is related to the slow onset of antinociceptive activity in the central nervous system. J. Pharmacol. Exp. Ther. 310(1), 177-184 (2004
104. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46(1-3), 247-279 (2001
105. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: A review. J. Pharm. Pharm. Sci. 6(2), 252-273 (2003
106. Schroeder U, Sommerfeld P, Sabel BA. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 19(4), 777-780 (1998
107. Dodda-Kashi SD, Lee VHL. Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: Similarities in rates and involvement of aminopeptidases. Life Sci. 38, 2019-2028 (1986
108. Lund L, Bak A, Friis GJ, Hovgaard L, Christrup LL. The enzymatic degradation and transport of leucine-enkephalin and 4-imidazolidinone enkephalin prodrugs at the blood-brain barrier. Int. J. Pharmaceutics, 172, 97-101 (1998
109. Alyautdin R, Gothier D, Petrov V, Kharkevitch D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41, 44-48 (1995
110. Das D, Lin S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci 94(6), 1343-1353 (2005
111. Kreuter J, Ramge P, Petrov V et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20(3), 409-416 (2003
112. Kreuter J, Shamenkov, D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood- brain barrier. J. Drug Target. 10(4), 317-325 (2002
113. Gessner A, Olbrich C, Schroder W, Kayser O, Muller RH. The role of plasma proteins in brain targeting: Species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int. J. Pharm. 214(1-2), 87-91 (2001
114. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16(12), 1836-1842 (1999
115. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 59(6), 454-477 (2007
116. Tobio M, Sanchez A, Vila A et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B Biointerfaces 18(3-4), 315-323 (2000
117. Gref R, Luck M, Quellec P et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces 18(3-4), 301-313 (2000
118. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47(1), 65-81 (2001
119. Hussain MA, Rowe SM, Shenvi AB, Aungst BJ. Inhibition of leucine enkephalin metabolism in rat blood, plasma and tissues in vitro by an aminoboronic acid derivative. Drug Metab. Dispos 18(3), 288-291 (1990
120. Siew A, Le H, Thiovolet M, Gellert P, Schatzlein A, Uchegbu I. Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol. Pharm. 9(1), 14-28 (2012
121. Garrett NL, Lalatsa A, Begley DJ et al. Label-free imaging of polymeric nanomedicines using coherent anti-stokes Raman scattering microscopy. J. Raman Spectr. 43(5), 681-688 (2011
122. Moulin DE, Max MB, Kaiko RF et al. The analgesic efficacy of intrathecal d-Ala2-d-Leu5-enkephalin in cancer patients with chronic pain. Pain 23(3), 213-221 (1985
123. Vadivelu N, Mitra S, Hines RL. Peripheral opioid receptor agonists for analgesia: A comprehensive review. J. Opioid Manag. 7(1), 55-68 (2011
124. Fitches EC, Pyati P, King GF, Gatehouse JA. Fusion to snowdrop lectin magnifies the oral activity of insecticidal omega-hexatoxin-hv1a peptide by enabling its delivery to the central nervous system. PLoS ONE 7(6), e39389 (2012
125. Chong Y, Hayes JL, Sollod B et al. The omega-atracotoxins: Selective blockers of insect M-LVA and HVA calcium channels. Biochem. Pharmacol. 74(4), 623-638 (2007